← Back

OBiO Technology (Shanghai) Corp. Ltd. A

Shanghai Obio Technology (Group) Corp., Ltd. is a biotechnology company that provides technical services in regenerative medicine and anti-aging in China and internationally. Its offerings include customized plasmid design, viral vector packaging, AAV serotypes, tissue-specific promoters, and research-grade, NHP-grade, and cGMP-grade vector manufacturing for basic research, translational research, and clinical trials. The company also provides CDMO services covering process development, analytical methods, IND-enabling chemistry, manufacturing, and controls, as well as clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products. It produces and sells biological raw materials, biological agents, and reagents. Formerly Obio Technology (Shanghai) Corp., Ltd., it changed its name to Shanghai Obio Technology (Group) Corp., Ltd. in March 2026, was founded in 2013, and is headquartered in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 688238.CG
688238.CG▼

Heyuan Bio reports net loss of 101 million yuan in 2026 interim results

Heyuan Bio has released its 2026 interim report, with net profit attributable to the parent company at minus 101 million yuan. Total operating revenue was 122 million yuan, and net cash flow from operating activities was minus 82.92 million yuan. The latest asset-liability ratio is 34.56 percent, up 2.49 percentage points from the previous quarter and up 7.09 percentage points from the same period last year. The latest gross margin is minus 7.89 percent, the latest return on equity is minus 7.75 percent, and diluted earnings per share is minus 0.16 yuan. The company has 14,600 shareholders, and the top ten shareholders hold 229 million shares, accounting for 35.34 percent of total share capital.
OBiO Technolog… ▼
688238.CG · Capital · Negative Company reports net loss of 101 million yuan in interim results.
Read original ↗
Jiemian·42dRead more →
China
688238.CG▼

Obio Technology's first-half net loss narrows to 101 million yuan

Obio Technology released its 2026 interim report, showing operating revenue of 122 million yuan, up 1.6 percent year on year, while net loss attributable to the parent company was 101 million yuan, narrowing from a loss of 105 million yuan in the same period last year. Second-quarter operating revenue was 71.25 million yuan, up 6.3 percent year on year, but the net loss attributable to the parent company was 48.33 million yuan, widening further from the same period last year. The company said revenue from its cell and gene therapy business was basically flat compared with the same period last year, while the CDMO business was affected by downstream investment and financing demand, and executed order prices remained at a relatively low level, resulting in a negative gross margin, though the overall loss showed a narrowing trend. As of the end of the second quarter, the company's total assets were 2.001 billion yuan, down 4.3 percent from the end of the previous year, and net assets attributable to the parent company were 1.308 billion yuan, down 7.1 percent from the end of the previous year.
OBiO Technolog… ▼
688238.CG · Capital · Negative Net loss widened in Q2 and CDMO business has negative gross margin due to low order prices.
Read original ↗
财中社·43dRead more →
Biotech & Genomic Medicine▲impact 4

China’s NMPA Proposes 30-Day Review Pathway for Cell and Gene Therapies

The General Office of the National Medical Products Administration has released a draft proposal to include eligible cell and gene therapy drugs in a 30-day review and approval pathway for innovative drug clinical trial applications. Previously, the review cycle was 60 working days, effectively doubling approval efficiency. The policy aligns with the forthcoming regulations on clinical research and translational application of new biomedical technologies, as well as the announcement issued last September on optimizing the review and approval of innovative drug clinical trials. Together, they enhance the industry ecosystem across multiple dimensions, including review efficiency, compliance pathways, and innovation orientation. The draft encourages global simultaneous development and international multi-center clinical trials, and focuses on key areas such as malignant tumors and rare diseases to guide resource concentration. Several A-share listed companies with a presence in the cell and gene therapy sector are expected to benefit, including Obio Technology, Pharmaron, and Porton Pharma Solutions. The Wind Innovative Drug Index has rebounded by more than 20 percent since mid-June.
OBiO Technolog… ▲Porton Fine Ch… ▲Pharmaron Beij… ▲
Biotech & Genomic Medicine ▲
About megatrends
Biotech & Genomic Medicine › Gene & Cell Editing ▲Regulation
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Regulation
688238.CG · Regulation · Positive China's NMPA proposes 30-day review pathway for cell and gene therapies, directly benefiting Obio Technology as a sector participant.
300363.CS · Regulation · Positive Porton Pharma Solutions is named as an expected beneficiary of the streamlined regulatory pathway for cell and gene therapies.
300759.CS · Regulation · Positive Pharmaron is listed as an A-share company expected to benefit from the NMPA's proposed faster review for cell and gene therapies.
Read original ↗
经济参考网·92dRead more →
© 2026 MarketIVAsset